Novel Parkinson Disease Drugs Aid in Reducing ‘Off’ Time in Patients

Digg This
Reddit This
Stumble Now!
Buzz This
Vote on DZone
Share on Facebook
Bookmark this on Delicious
Kick It on DotNetKicks.com
Shout it
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)
Contact Us
Shushmul Maheshwari
G-199,, Sector-63
Noida
Uttar Pradesh 201301 
India
Phone:1204224700
Fax:1204224700
press@rncos.com

Parkinson’s disease is a complex progressive movement disorder. This disorder leads to the development of motor and non-motor symptoms, which have the tendency to become increasingly debilitating as the disease advances. Several medications, such as levodopa therapy, are available in the market for the treatment of these symptoms.

As per our latest report “Global Parkinson’s Disease Drugs Market Outlook 2022″, the patients taking these medications often experience “off” time during treatment period. According to the USFDA, an ‘off’ episode is a time when a patient’s medications are not working well. An increase in Parkinson’s symptoms, like decrease in motor and non-motor functions, is witnessed during “off” time. In addition, mainly as a result of excessive oral doses of levodopa aimed at treating the ‘off’ time, some patients experience dyskinesia or involuntary movements.

The ‘off’ time and dyskinesia affect majority of Parkinson’s disease patients. It also interferes with day-to-day functions of Parkinson’s patients, causing them to become severely disabled and degrading their quality of life. Furthermore, it also increases the economic burden on the patient and their family members, as more drugs are required to shrink ‘off’ time.

To overcome this hurdle, pharmaceutical companies and research institutes are developing strategies to develop novel therapies, which will help in reducing ‘off’ time in Parkinson’s patients. For instance, Xadago is a medication that was approved by the USFDA in 2017 for Parkinson’s disease treatment. This drug is once-daily tablet for Parkinson’s disease patients as an add-on to levodopa/carbidopa. It is given when patients experience ‘off’ episodes. Xadago provides a better ‘on’ time without the occurrence of dyskinesia. This medication will help in improving the quality of life of Parkinson’s disease patients with better motor functions.

Therefore, developing more of such medications which help in reducing ‘off’ time will be a great strategy to improve the patient and economic outcomes. They will also provide opportunities for the growth of global Parkinson’s disease drugs market.

For FREE SAMPLE of this report visit: http://rncos.viewpage.co/Global-Parkinsons-Disease-Drugs-Market-Outlook-2022

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

ABOUT RNCOS

RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.

Comments are closed.